Keyword: Tmunity Therapeutics
Scientists running the first trial of CRISPR-edited cells to fight cancer are reporting that the therapy has been well tolerated by three patients.
Tmunity is coming back to the well for a $75 million series B that will take it into phase 2 studies in 2021.
Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.
Tmunity Therapeutics has licensed a T-cell receptor treatment from UCSF and aims to start human trials by 2021.
What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
In 2019, Tmunity hopes to share data from its lead T cell programs and announce new solid tumor targets.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
Boehringer’s Corsico jumps to head dev at GSK; Kite’s Polverino takes CSO role at Zymeworks; and Kymera taps former Alnylam executive as CMO.
Tmunity is working on better and safer T-cell treatments for solid tumors and blood cancers.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.
